Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies
De Ville De Goyet, Maëlle; Kicinski, Michal; Suciu, Stefanet al.
_Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies.pdf
Cancer Research; Endocrine and Autonomic Systems; Endocrinology; Oncology; Endocrinology, Diabetes and Metabolism
Abstract :
[en] Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and radiotherapy. This observational retrospective study evaluated the cumulative incidence of neurological late effects among 890 childhood ALL survivors treated in EORTC CLG trials (58741, 58831/2 and 58881) between 1971 and 1998. Median follow-up was 19 years and interquartile range of the follow-up was 15-22 years. At 20 years from the end of treatment, approximately 66% of patients from the 58741 trial (accrual time: 1971-1978) and approximately 15% from the more recent trials had cognitive disturbance grade 1 or higher. Cumulative incidences at 20 years from treatment end of seizures, stroke and leukoencephalopathy were respectively 45%, 16% and 62% in study 58741, 13%, 2% and 5% in study 58831/2, and 8%, 2% and 3% in study 58881. Patients who were 10-17 years of age at diagnosis had a higher incidence of stroke and leukoencephalopathy as compared to those less than 6 years of age. Noteworthy, all neurological late effects continued to occur beyond 5 years after end of treatment. This retrospective study highlights the frequency of neurological late effects in survivors of childhood ALL. With the increase of the overall survival of ALL patients, the role and potential
Disciplines :
Pediatrics Hematology Oncology
Author, co-author :
De Ville De Goyet, Maëlle; Department of Paediatric Haematology-Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies
KU Leuven - Catholic University of Leuven Kinderkankerfonds - vzw Kinderkankerfonds FOCA - Fonds Cancer
Funding text :
This publication was supported by donations from the Fonds Cancer (FOCA) from Belgium and from KU Leuven from Belgium. C.Pi.
has been awarded a fellowship by Fonds Cancer (FOCA) from Belgium and the Kinderkankerfonds from Belgium (a non-profit childhood
cancer foundation under Belgian law).
Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938–48. 10.1200/JCO.2014.59.1636. DOI: 10.1200/JCO.2014.59.1636
Nathan PC, Ford JS, Henderson TO, et al. Health behaviors, medical care, and interventions to promote healthy living in the childhood cancer survivor study cohort. J Clin Oncol. 2009;27(14):2363–73. 10.1200/JCO.2008.21.1441. DOI: 10.1200/JCO.2008.21.1441
Krull KR, Brinkman TM, Li C, et al. Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(35):4407–15. 10.1200/JCO.2012.48.2315. DOI: 10.1200/JCO.2012.48.2315
Cheung YT, Krull KR. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: a systematic review. Neurosci Biobehav Rev. 2015;53:108–20. 10.1016/j.neubiorev.2015.03.016. DOI: 10.1016/j.neubiorev.2015.03.016
Schuitema I, Deprez S, van Hecke W, et al. Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol. 2013;31(27):3378–88. 10.1200/JCO.2012.46.7050. DOI: 10.1200/JCO.2012.46.7050
Edelmann MN, Ogg RJ, Scoggins MA, et al. Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: a report from the SJLIFE cohort. Pediatr Blood Cancer. 2013;60:1778–84. DOI: 10.1002/pbc.24644
Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood. 2009;114(9):1746–52. DOI: 10.1182/blood-2008-12-186502
Huang IC, Brinkman TM, Kenzik K, et al. Association between the prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer: a report from the St Jude lifetime cohort study. J Clin Oncol. 2013;31(33):4242–51. 10.1200/JCO.2012.47.8867. DOI: 10.1200/JCO.2012.47.8867
Muffly L, Maguire FB, Li Q, Kennedy V, Keegan TH. Late effects in survivors of adolescent and young adult acute lymphoblastic leukemia. JNCI Cancer Spectr. 2020. 10.1093/jncics/pkaa025. DOI: 10.1093/jncics/pkaa025
Maytal J, Grossman R, Yusuf FH, et al. Prognosis and treatment of eizures in children with acute lymphoblastic leukemia. Epilepsia. 1995;36(8):831–6. 10.1111/j.1528-1157.1995.tb01622.x. DOI: 10.1111/j.1528-1157.1995.tb01622.x
Duval M. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer—Children’s Leukemia Group phase 3 trial. Blood. 2002;99(8):2734–9. 10.1182/blood.V99.8.2734. DOI: 10.1182/blood.V99.8.2734
Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–59. 10.1200/JCO.2013.53.0808. DOI: 10.1200/JCO.2013.53.0808
Piette C, de Rojas T, Suciu S, et al. Lessons learnt from the medical and psychosocial evaluation of childhood acute lymphoblastic leukemia (ALL) survivors enrolled in EORTC Children Leukemia Group Trials between 1971 and 1998 and future perspectives for long-term outcome research. J Cancer Policy. 2018;15:82–6. 10.1016/J.JCPO.2018.02.006. DOI: 10.1016/J.JCPO.2018.02.006
Rossi G, Kicinski M, Suciu S, et al. Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between, and 1998 in EORTC CLG studies: results of the 58 late adverse effects study. Human Reprod. 1971. 10.1093/humrep/deab236. DOI: 10.1093/humrep/deab236
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 4.0. Bethesda: National Institutes of Health National Cancer Institute; 2009.
Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov Chains Based on censored observations. Scand J Stat. 1978;5(3):141–50. 10.2307/4615704. DOI: 10.2307/4615704
Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. 10.2307/2670170. DOI: 10.2307/2670170
Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken: Wiley; 1987. DOI: 10.1002/9780470316696
Delord M, Génin E. Multiple imputation for competing risks regression with interval-censored data. J Stat Comput Simul. 2015;86(11):1–12. 10.1080/00949655.2015.1106543. DOI: 10.1080/00949655.2015.1106543
Kosmin M, Rees J. Radiation and the nervous system. Pract Neurol. 2022;22:450–60. 10.1136/pn-2022-003343. DOI: 10.1136/pn-2022-003343
Piette C, Suciu S, Bertrand Y, et al. Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study. Br J of Haematol. 2020;189(2):351–62. 10.1111/bjh.16337. DOI: 10.1111/bjh.16337
Nassar SL, Conklin HM, Zhou Y, et al. Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64(8): e26436. 10.1002/pbc.26436. DOI: 10.1002/pbc.26436
Pryweller JR, Glass JO, Sabin ND, et al. Characterization of leukoencephalopathy and association with later neurocognitive performance in pediatric acute lymphoblastic leukemia. Invest Radiol. 2021;56(2):117–26. 10.1097/RLI.0000000000000715. DOI: 10.1097/RLI.0000000000000715
Renard M, Suciu S, Bertrand Y, et al. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours. Pediatr Blood Cancer. 2011;57(1):119–25. 10.1002/pbc.23083. DOI: 10.1002/pbc.23083